View Older Stories View More Recent Stories

Jan 22, 2024 07:00AM Invitae Completes Sale of Reproductive Health Assets to Natera
Jun 5, 2023 11:06AM Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer
May 15, 2023 04:08PM InVitae (NVTA) to Appeal Trial Verdict Against Natera (NTRA)
Nov 9, 2022 09:00AM Day Zero Diagnostics Welcomes Healthcare Business Leader Gail Marcus to its Board
Aug 25, 2022 08:35AM Natera Earns Great Place to Work Certification™ for Second Consecutive Year
Mar 23, 2022 07:30AM Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
Jun 24, 2021 09:03AM Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China
Jun 8, 2021 07:03AM Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
Jun 8, 2021 07:00AM Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
Feb 17, 2021 09:01AM Natera and Personalis Partner for Personalized Monitoring in Oncology
Feb 17, 2021 09:00AM Natera and Personalis Partner for Personalized Monitoring in Oncology
Feb 11, 2020 09:06AM Elicio Therapeutics and Natera (NTRA) to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002
Feb 11, 2020 09:05AM Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002
Feb 11, 2020 09:05AM Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002
Sep 25, 2019 09:03AM Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring
Sep 24, 2019 07:00AM Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring
May 6, 2019 11:56AM Natera (NTRA) Announces FDA Granted Breakthrough Device Designation to its Signatera Test
May 6, 2019 11:55AM FDA Grants Breakthrough Device Designation to Natera's Signatera Test
May 2, 2019 08:51PM Natera Announces First Quarter 2019 Earnings Conference Call
Apr 10, 2019 08:03AM Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma
Mar 11, 2019 06:07AM Natera (NTRA) Reports $50M Partnership with BGI Genomics Co. Ltd. to Commercialize Signatera MRD test in China & Develop Reproductive Health Tests in Select Markets
Mar 11, 2019 06:03AM Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform
Mar 5, 2019 02:17PM Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call
Mar 5, 2019 02:17PM /C O R R E C T I O N -- Natera, Inc./
Feb 22, 2019 09:03AM Natera (NTRA) Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay
Feb 22, 2019 09:00AM Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay
Feb 19, 2019 01:46PM Natera Presents Outcomes Data at SMFM Annual Meeting Showing Strong Clinical Performance of Its SNP-Based Non-Invasive Prenatal Test
Feb 1, 2019 07:30AM Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Jan 7, 2019 08:03AM Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection
Jan 4, 2019 02:02PM Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Jan 4, 2019 08:48AM Natera (NTRA) Secures Z-Codes for Signatera MRD and Treatment Monitoring Test, Ahead of Planned Clinical Launch in 2Q19
Jan 4, 2019 08:03AM Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology
Jan 2, 2019 04:06PM Natera (NTRA) Announces Steve Chapman as CEO & Robert Schueren as COO; Appoints Co-Founder & CEO to Executive Chairman Position
Jan 2, 2019 04:02PM Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman
Dec 6, 2018 08:03AM Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response
Nov 29, 2018 08:04AM Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study
Nov 28, 2018 08:03AM Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test
Nov 1, 2018 11:00AM Natera Announces Third Quarter 2018 Earnings Conference Call
Oct 18, 2018 04:20PM Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Oct 18, 2018 04:15PM Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Sep 13, 2018 01:05PM Natera (NTRA) Enters Agreement with Bristol-Myers (BMY) for Signatera ctDNA Assay
Sep 13, 2018 01:02PM Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera™ ctDNA Assay as a Potential Biomarker for Opdivo (nivolumab) in a Prospective Phase 2 Adjuvant Non-Small Cell Lung Cancer Cl
Aug 15, 2018 12:41PM Natera and Fox Chase Cancer Center to Collaborate on Kidney Cancer Study
Aug 7, 2018 02:50PM Natera Clinical Study Validates New Biomarker for Aneuploidy and Adverse Pregnancy Outcomes
Aug 2, 2018 08:06AM Study Shows Natera's Spectrum Preimplantation Genetic Testing for Aneuploidy Improves IVF Outcomes for All Women, Regardless of Maternal Age
Aug 1, 2018 12:46PM Natera, Inc. Announces Second Quarter 2018 Earnings Conference Call
Jul 31, 2018 11:06AM Natera (NTRA) Names Roy Baynes to Board
Jul 31, 2018 11:00AM Natera Appoints Roy Baynes to Board of Directors, Adding Deep Oncology Experience
Jun 21, 2018 03:01PM Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology
Jun 21, 2018 02:57PM Natera (NTRA) Announces Powerful Kidney Transplant Rejection Biomarker
View More Recent Stories View Older Stories